Involvement of SAPK/JNK in basic fibroblast growth factor-induced vascular endothelial growth factor release in osteoblasts

in Journal of Endocrinology
Authors:
H Tokuda
Search for other papers by H Tokuda in
Current site
Google Scholar
PubMed
Close
,
K Hirade
Search for other papers by K Hirade in
Current site
Google Scholar
PubMed
Close
,
X Wang
Search for other papers by X Wang in
Current site
Google Scholar
PubMed
Close
,
Y Oiso
Search for other papers by Y Oiso in
Current site
Google Scholar
PubMed
Close
, and
O Kozawa
Search for other papers by O Kozawa in
Current site
Google Scholar
PubMed
Close
Free access

Sign up for journal news

We previously reported that basic fibroblast growth factor (FGF-2) activates p44/p42 mitogen-activated protein (MAP) kinase resulting in the stimulation of vascular endothelial growth factor (VEGF) release in osteoblast-like MC3T3-E1 cells and that FGF-2-activated p38 MAP kinase negatively regulates VEGF release. In the present study, we investigated the involvement of stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) in FGF-2-induced VEGF release in these cells. FGF-2 markedly induced the phosphorylation of SAPK/JNK. SP600125, an inhibitor of SAPK/JNK, markedly reduced the FGF-2-induced VEGF release. SP600125 suppressed the FGF-2-induced phosphorylation of SAPK/JNK without affecting the phosphorylation of p44/p42 MAP kinase or p38 MAP kinase induced by FGF-2. PD98059, an inhibitor of upstream kinase of p44/p42 MAP kinase, or SB203580, an inhibitor of p38 MAP kinase, failed to affect the FGF-2-induced phosphorylation of SAPK/JNK. A combination of SP600125 and SB203580 suppressed the FGF-2-stimulated VEGF release in an additive manner. These results strongly suggest that FGF-2 activates SAPK/JNK in osteoblasts, and that SAPK/JNK plays a part in FGF-2-induced VEGF release.

 

  • Collapse
  • Expand